18 September 2013 | Analysis | By BioSpectrum Bureau
Majority of the APAC CROs continue to serve a small, dedicated set of less than 50 clients
The fifth edition of the annual BioSpectrum Asia Pacific clinical research organization (CRO) Survey, which is conducted in association with CyberMedia Research (CMR), yet again identifies the latest trends, issues, perspectives and insights regarding the CRO industry in Asia Pacific (APAC).
While the 2013 survey revealed many hindrances facing the industry, including lack of optimum regulatory efficiency, training of personnel, limited development partnerships between CROs and pharma firms; it also reveales many promising findings, including high willingness to participate in clinical trials among countries like China, India, Australia, Korea, Taiwan, Malaysia, Philippines and Indonesia. Furthermore, the CRO sector in APAC is witnessing a major boom leveraging on the growth of logistics and supply chain management in the region.
As many as 27 percent of the survey respondents of the fifth BioSpectrum Asia-CMR Asia Pacific Annual Survey of the Clinical and Contract Research Organizations 2013 indicate that the average number of clients serviced by them per year is more than 50. In 2012, 23 percent of the survey respondents had indicated clientele of more than 50 clients.
Moreover, an overwhelming majority of the Asia Pacific CROs continue to serve a small, dedicated clientele set of less than 50 clients.